Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Intangibles (2018 - 2023)

Sangamo Therapeutics has reported Intangibles over the past 8 years, most recently at $51.6 million for Q1 2023.

  • Quarterly results put Intangibles at $51.6 million for Q1 2023, down 2.13% from a year ago — trailing twelve months through Mar 2023 was $51.6 million (down 2.13% YoY), and the annual figure for FY2022 was $50.7 million, down 5.64%.
  • Intangibles for Q1 2023 was $51.6 million at Sangamo Therapeutics, up from $50.7 million in the prior quarter.
  • Over the last five years, Intangibles for SGMO hit a ceiling of $58.1 million in Q4 2020 and a floor of $46.4 million in Q3 2022.
  • Median Intangibles over the past 5 years was $53.2 million (2019), compared with a mean of $53.1 million.
  • Biggest five-year swings in Intangibles: rose 9.35% in 2020 and later fell 15.45% in 2022.
  • Sangamo Therapeutics' Intangibles stood at $53.2 million in 2019, then grew by 9.35% to $58.1 million in 2020, then decreased by 7.51% to $53.8 million in 2021, then fell by 5.64% to $50.7 million in 2022, then increased by 1.63% to $51.6 million in 2023.
  • The last three reported values for Intangibles were $51.6 million (Q1 2023), $50.7 million (Q4 2022), and $46.4 million (Q3 2022) per Business Quant data.